Business Context and Reporting Period
This Form 8-K filing by Calyxt, Inc. (not Cibus, Inc.) reports a corporate governance event. The report date is July 10, 2018, covering an event that occurred on July 3, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of a new Board member:
- Appointment: Dr. Yves Joseph Ribeill, Ph.D., was elected to the Board of Directors effective July 3, 2018.
- Committee Assignment: Dr. Ribeill was appointed to the Audit Committee.
- Qualifications: The Board determined Dr. Ribeill is an independent director and qualifies as an "audit committee financial expert."
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details Dr. Ribeill's background, including his role as CEO of COREzonada, Inc., his founding of Scynexis, Inc., and his 25-year career with Rhone-Poulenc and Aventis. He will receive compensation in accordance with standard arrangements for non-employee directors and has been provided an indemnification agreement.
Investor Verification Checklist
- Verify the correct registrant name is Calyxt, Inc., not Cibus, Inc.
- Confirm Dr. Yves Joseph Ribeill's independence status and financial expertise qualifications.
- Review the company's standard compensation arrangements for non-employee directors.
- Check for any subsequent filings regarding Dr. Ribeill's tenure or committee assignments.